PT1450770E - Composicao farmaceutica compreendendo um agonista do receptor 5ht1 - Google Patents

Composicao farmaceutica compreendendo um agonista do receptor 5ht1

Info

Publication number: PT1450770E
Authority: PT; Portugal
Prior art keywords: pharmaceutical composition; receptor agonist; composition understanding; understanding; agonist
Prior art date: 2001-12-05

Application number

PT02792887T

Other languages

English (en)

Inventor

Baker Robert William

Dow Alan David

Summers Simon John

Westrup Julian

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-05

Filing date

2002-12-04

Publication date

2005-08-31

2002-12-04 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2005-08-31 Publication of PT1450770E publication Critical patent/PT1450770E/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT02792887T 2001-12-05 2002-12-04 Composicao farmaceutica compreendendo um agonista do receptor 5ht1 PT1450770E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0129117.8A GB0129117D0 (en)	2001-12-05	2001-12-05	Pharmaceutical composition

Publications (1)

Publication Number	Publication Date
PT1450770E true PT1450770E (pt)	2005-08-31

Family

ID=9927051

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT02792887T PT1450770E (pt)	2001-12-05	2002-12-04	Composicao farmaceutica compreendendo um agonista do receptor 5ht1

Country Status (29)

Country	Link
US (1)	US20050032867A1 (pt)
EP (2)	EP1450770B1 (pt)
JP (1)	JP3699969B2 (pt)
KR (1)	KR100591237B1 (pt)
CN (1)	CN1289069C (pt)
AR (1)	AR037627A1 (pt)
AT (1)	ATE291900T1 (pt)
AU (1)	AU2002358602B2 (pt)
BR (1)	BR0214497A (pt)
CA (1)	CA2469019C (pt)
CO (1)	CO5580741A2 (pt)
DE (1)	DE60203537T2 (pt)
ES (1)	ES2236608T3 (pt)
FI (1)	FI20022128A (pt)
GB (1)	GB0129117D0 (pt)
HK (1)	HK1069111A1 (pt)
HU (1)	HU229313B1 (pt)
IL (1)	IL161997A (pt)
IS (1)	IS2481B (pt)
MX (1)	MXPA04005420A (pt)
MY (1)	MY129314A (pt)
NO (1)	NO329896B1 (pt)
NZ (1)	NZ532829A (pt)
PL (1)	PL194702B1 (pt)
PT (1)	PT1450770E (pt)
RU (1)	RU2285526C2 (pt)
TW (1)	TWI240638B (pt)
WO (1)	WO2003047552A2 (pt)
ZA (1)	ZA200403849B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8071128B2 (en)	1996-06-14	2011-12-06	Kyowa Hakko Kirin Co., Ltd.	Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en)	2001-10-04	2016-06-07	Adare Pharmaceuticals, Inc.	Timed, sustained release systems for propranolol
US8367111B2 (en)	2002-12-31	2013-02-05	Aptalis Pharmatech, Inc.	Extended release dosage forms of propranolol hydrochloride
MXPA05010070A (es)	2003-04-11	2005-11-23	Pfizer	Combinacion farmaceutica.
BRPI0410807A (pt) *	2003-06-06	2006-06-27	Glaxo Group Ltd	composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica
US8216610B2 (en)	2004-05-28	2012-07-10	Imaginot Pty Ltd.	Oral paracetamol formulations
EP1750677B1 (en) *	2004-05-28	2017-02-01	Imaginot Pty Ltd.	Oral therapeutic compound delivery system
US8747895B2 (en)	2004-09-13	2014-06-10	Aptalis Pharmatech, Inc.	Orally disintegrating tablets of atomoxetine
US9884014B2 (en)	2004-10-12	2018-02-06	Adare Pharmaceuticals, Inc.	Taste-masked pharmaceutical compositions
US20060105039A1 (en)	2004-10-21	2006-05-18	Jin-Wang Lai	Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en)	2005-05-02	2015-10-20	Adare Pharmaceuticals, Inc.	Timed, pulsatile release systems
EP3263117A1 (en)	2005-11-28	2018-01-03	Imaginot Pty Ltd.	Oral therapeutic compound delivery system
CN101431895A (zh) *	2006-05-01	2009-05-13	卡普里康制药公司	新颖的曲坦制剂和制备它们的方法
WO2008039358A2 (en) *	2006-09-30	2008-04-03	Capricorn Pharma Inc.	Resin-complex granulation for water-soluble drugs and associated methods
RU2563623C2 (ru)	2009-12-02	2015-09-20	Апталис Фарма Лимитед	Микрокапсулы фексофенадина и содержащие их композиции
US11364225B2 (en)	2019-08-21	2022-06-21	Bn Intellectual Properties, Inc.	Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5468504A (en) *	1990-12-21	1995-11-21	Laboratoires Glaxo S.A.	Effervescent pharmaceutical compositions
GB9027827D0 (en) *	1990-12-21	1991-02-13	Glaxo Laboratoires	Pharmaceutical compositions
GB9104890D0 (en) *	1991-03-08	1991-04-24	Glaxo Group Ltd	Compositions
US5460972A (en) *	1991-04-08	1995-10-24	Research Foundation Of The State University Of New York	Ionized magnesium2+ concentrations in biological samples
US6649186B1 (en) *	1996-09-20	2003-11-18	Ethypharm	Effervescent granules and methods for their preparation
GB9704524D0 (en) *	1997-03-05	1997-04-23	Smithkline Beecham Plc	Composition
GB9706089D0 (en) *	1997-03-24	1997-05-14	Scherer Ltd R P	Pharmaceutical composition
WO1999043306A1 (en) *	1998-02-26	1999-09-02	Banyu Pharmaceutical Co., Ltd.	An orally disintegrating composition and its manufacturing method
US6350470B1 (en) *	1998-04-29	2002-02-26	Cima Labs Inc.	Effervescent drug delivery system for oral administration
US6383471B1 (en) *	1999-04-06	2002-05-07	Lipocine, Inc.	Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6264981B1 (en) *	1999-10-27	2001-07-24	Anesta Corporation	Oral transmucosal drug dosage using solid solution
CA2392810A1 (en) *	1999-12-01	2001-06-07	Natco Pharma Limited	A rapid acting freeze dired oral pharmaceutical composition for treating migraine
KR20010107754A (ko) *	2000-05-26	2001-12-07	민경윤	경구투여용 속용정의 제조 방법
US20030008005A1 (en) *	2001-07-05	2003-01-09	R.T. Alamo Ventures, Inc.	Sublingual administration of dihydroergotamine for the treatment of migraine

2001
- 2001-12-05 GB GBGB0129117.8A patent/GB0129117D0/en not_active Ceased
2002
- 2002-12-03 FI FI20022128A patent/FI20022128A/fi not_active Application Discontinuation
- 2002-12-03 TW TW091134979A patent/TWI240638B/zh not_active IP Right Cessation
- 2002-12-03 MY MYPI20024534A patent/MY129314A/en unknown
- 2002-12-03 AR ARP020104674A patent/AR037627A1/es unknown
- 2002-12-03 NO NO20025805A patent/NO329896B1/no not_active IP Right Cessation
- 2002-12-04 JP JP2003548808A patent/JP3699969B2/ja not_active Expired - Lifetime
- 2002-12-04 EP EP02792887A patent/EP1450770B1/en not_active Expired - Lifetime
- 2002-12-04 AU AU2002358602A patent/AU2002358602B2/en not_active Expired
- 2002-12-04 BR BR0214497-2A patent/BR0214497A/pt not_active Application Discontinuation
- 2002-12-04 HU HU0402178A patent/HU229313B1/hu unknown
- 2002-12-04 PL PL02370669A patent/PL194702B1/pl unknown
- 2002-12-04 PT PT02792887T patent/PT1450770E/pt unknown
- 2002-12-04 MX MXPA04005420A patent/MXPA04005420A/es active IP Right Grant
- 2002-12-04 CN CNB028244184A patent/CN1289069C/zh not_active Expired - Fee Related
- 2002-12-04 NZ NZ532829A patent/NZ532829A/en not_active IP Right Cessation
- 2002-12-04 CA CA002469019A patent/CA2469019C/en not_active Expired - Lifetime
- 2002-12-04 EP EP05075288A patent/EP1527773A1/en not_active Withdrawn
- 2002-12-04 RU RU2004120292/15A patent/RU2285526C2/ru not_active IP Right Cessation
- 2002-12-04 KR KR1020047008687A patent/KR100591237B1/ko active IP Right Grant
- 2002-12-04 AT AT02792887T patent/ATE291900T1/de active
- 2002-12-04 IL IL16199702A patent/IL161997A/xx active IP Right Grant
- 2002-12-04 DE DE60203537T patent/DE60203537T2/de not_active Expired - Lifetime
- 2002-12-04 ES ES02792887T patent/ES2236608T3/es not_active Expired - Lifetime
- 2002-12-04 WO PCT/EP2002/013715 patent/WO2003047552A2/en active IP Right Grant
- 2002-12-04 US US10/497,749 patent/US20050032867A1/en not_active Abandoned
2004
- 2004-05-19 ZA ZA2004/03849A patent/ZA200403849B/en unknown
- 2004-06-03 CO CO04052110A patent/CO5580741A2/es active IP Right Grant
- 2004-06-03 IS IS7293A patent/IS2481B/is unknown
2005
- 2005-02-28 HK HK05101699A patent/HK1069111A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU2002358602B2 (en)	2005-05-26
NO20025805L (no)	2003-06-06
EP1450770A2 (en)	2004-09-01
EP1527773A1 (en)	2005-05-04
AU2002358602A1 (en)	2003-06-17
HUP0402178A3 (en)	2011-05-30
IL161997A (en)	2005-12-18
US20050032867A1 (en)	2005-02-10
RU2285526C2 (ru)	2006-10-20
WO2003047552A2 (en)	2003-06-12
NO20025805D0 (no)	2002-12-03
IS2481B (is)	2008-12-15
HU229313B1 (en)	2013-10-28
DE60203537T2 (de)	2005-09-15
FI20022128A0 (fi)	2002-12-03
MXPA04005420A (es)	2004-10-11
JP2005515991A (ja)	2005-06-02
HUP0402178A2 (hu)	2005-02-28
PL370669A1 (en)	2005-05-30
JP3699969B2 (ja)	2005-09-28
IS7293A (is)	2004-06-03
NZ532829A (en)	2005-05-27
MY129314A (en)	2007-03-30
CA2469019C (en)	2005-09-13
CN1610539A (zh)	2005-04-27
WO2003047552A3 (en)	2003-09-25
BR0214497A (pt)	2004-10-19
NO329896B1 (no)	2011-01-24
ZA200403849B (en)	2005-10-26
GB0129117D0 (en)	2002-01-23
CO5580741A2 (es)	2005-11-30
FI20022128A (fi)	2003-06-06
ES2236608T3 (es)	2005-07-16
ATE291900T1 (de)	2005-04-15
HK1069111A1 (en)	2005-05-13
TWI240638B (en)	2005-10-01
CA2469019A1 (en)	2003-06-12
RU2004120292A (ru)	2005-04-10
EP1450770B1 (en)	2005-03-30
IL161997A0 (en)	2005-11-20
PL194702B1 (pl)	2007-06-29
KR20050044720A (ko)	2005-05-12
CN1289069C (zh)	2006-12-13
KR100591237B1 (ko)	2006-06-19
TW200304384A (en)	2003-10-01
AR037627A1 (es)	2004-11-17
DE60203537D1 (de)	2005-05-04

Publication	Publication Date	Title
NO20032678D0 (no)	2003-06-12	NMDA reseptor agonist farmasöytiske sammensetninger
DK1446379T3 (da)	2009-07-27	Arylanilin-beta2-adrenergiske receptoragonister
PT1450770E (pt)	2005-08-31	Composicao farmaceutica compreendendo um agonista do receptor 5ht1
DK1455756T3 (da)	2008-11-17	Farmaceutisk nanopartikelformig sammensætning af en Tachykinin-receptor-antagonist
FI20011478A0 (fi)	2001-07-05	Farmaseuttinen koostumus
FIU20060387U0 (fi)	2006-09-22	Lantaaniyhdisteitä käsittävä farmaseuttinen koostumus
PT1467724E (pt)	2006-08-31	Composicao farmaceutica orodispersavel de agomelatina
EG24194A (en)	2008-10-14	5ht-a-partial agonist pharmaceutical compositions
EE200300589A (et)	2004-02-16	Ravimkoostised
NO20042737L (no)	2004-08-17	Peroksisomproliferatoraktiverte receptoragonister
NO20034556D0 (no)	2003-10-10	Imidazotriazinon-holdige sammensetninger for nasal administrering
DE60217390D1 (de)	2007-02-15	Bicalutamid enthaltende pharmazeutische zusammensetzung
DE10291905D2 (de)	2004-05-27	Pharmazeutische Zusammensetzung
IS7581A (is)	2004-12-03	Lyfjasamsetning
NO20013978L (no)	2001-08-15	Dopamin D1 reseptor agonist forbindelser
ATE350029T1 (de)	2007-01-15	Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
DK1450770T3 (da)	2005-08-01	Farmaceutisk præparat, der omfatter en 5HT1-receptoragonist
EE200300378A (et)	2003-10-15	Farmatseutiline kompositsioon
FI20012242A0 (fi)	2001-11-19	Uudet farmaseuttiset yhdisteet
DK1347760T3 (da)	2005-09-05	Farmaceutiske kompositioner med NMDA receptor agonister
FI5468U1 (fi)	2002-07-30	Farmaseuttinen koostumus
DOP2002000508A (es)	2003-06-15	Composición farmaceutica
SE0200008D0 (sv)	2002-01-02	New pharmaceutically compounds
SE0100847D0 (sv)	2001-03-09	Novel pharmaceutical composition
ITMI20020926A0 (it)	2002-04-30	Composizioni farmaceutiche riepitelizzanti